BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...four are categorized as antivirals, two as immunosuppresants, and one as a metabolic modulator.TargetsCathepsin L (CTSL)eIF4E –...
BioCentury | Aug 7, 2020

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic....
BioCentury | Jun 24, 2020

Expect more company creation by BGV with its €105M fourth fund

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...
BioCentury | Jun 22, 2020

In a first for the British Business Bank, firm backs Epidarex’s new fund

Epidarex’s latest fund will give the trans-Atlantic firm the ability to retain larger stakes later into the life cycle of portfolio companies. The fund also marks the first life sciences cornerstone investment from the British...
BioCentury | Jun 11, 2020

Prism’s peptide mimetic platform finds second discovery partner

...undisclosed CNS indication. Targets CTNNB1 - β-catenin CREBBP (CBP) - CREB binding protein eIF4EBP1 - Eukaryotic translation initiation factor 4E...
BioCentury | Apr 29, 2020

Kurma closes new fund at €160M, triple size of previous fund

Kurma Partners is the latest European life sciences VC to raise a record fund. The French VC announced the final close of Kurma Biofund III at €160 million ($173.4 million), nearly three times the size...
BioCentury | Apr 18, 2020

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

...lab of Harvard University professor Gerhard Wagner, aims to block oncogene protein production by inhibiting eIF4E...
...II testing for prostate cancer, to Oncology Venture A/S (SSE:OV) in 2015. Targets eIF4E - Eukaryotic translation initiation factor 4E Elizabeth...
BioCentury | Mar 31, 2020

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BioCentury | Mar 10, 2020

LSP to deploy $600M fund to retain larger stakes in early-stage European biotechs

LSP has formally closed its sixth fund at $600 million, the largest ever for a European life sciences fund. The firm joins a growing number of European VCs that have announced record fund-raisings in recent...
Items per page:
1 - 10 of 217